From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma - Takeaways - MDSpire

From relapse to survival: real-world clinical impact of a multimodal approach in first-time recurrent glioblastoma

  • By

  • Jean-Baptiste Barbe-Richaud

  • Hélène Cebula

  • Julien Todeschi

  • Marie des Neiges Santin

  • Seyyid Baloglu

  • Roland Schott

  • Mathieu Cotton

  • Aurélien Blouet

  • Maxime Bobin

  • Georges Noël

  • Laura Somme

  • June 23, 2026

  • 0 min

Share

  • 1

    The FROST study investigates the effectiveness of multimodal strategies for treating first-time recurrent glioblastoma.

  • 2

    Glioblastoma is the most common malignant brain tumor in adults, typically diagnosed after age 65, with a poor prognosis.

  • 3

    Current treatment for glioblastoma includes maximal surgical resection, radiotherapy, and temozolomide, but recurrence occurs in about 75% of patients.

  • 4

    The study evaluates various treatment strategies, including systemic therapy, local monotherapy, and multimodal approaches, for overall survival.

  • 5

    Overall survival is measured from the start of initial treatment until death, with a focus on the impact of different therapeutic strategies.

Original Source(s)

Related Content